CLK2 and non-small cell lung carcinoma: Increased expression of CLK2 was demonstrated to be correlated with poor prognosis in non-small cell lung cancer (NSCLC).121 In addition, CLK2 expression was elevated in patients with late-stage (III–IV) cancer and metastasis, indicating that CLK2 could be a potential biomarker in NSCLC.